Form 4: Catalyst Pharmaceuticals Executive Sells Shares After Option Exercise
SEC Form 4 Filing
Gary Ingenito, Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals, sold 38,000 shares after exercising options at a lower price.
Summary
- Gary Ingenito, the Chief Medical and Regulatory Officer of Catalyst Pharmaceuticals, executed a transaction involving the company's stock on November 20, 2024.
- He exercised options to purchase 38,000 shares of common stock at a price of $4.01 per share.
- Following the exercise, he sold the same 38,000 shares on the open market at a weighted average price of $21.199 per share.
- The sales were conducted in multiple lots with prices ranging from $21.18 to $21.27 per share.
- After these transactions, Ingenito directly owns 51,391 shares of common stock and 912,575 options to purchase common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction by an executive, with no indication of positive or negative sentiment towards the company's performance. It is a neutral event.
Management Comments
- Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
Industry Context
This is a routine transaction for a company executive exercising stock options and selling shares. It is common for executives to exercise options and sell shares for personal financial management.
Comparison to Industry Standards
- Executive stock option exercises and sales are a common practice across the pharmaceutical industry.
- The price difference between the exercise price and the sale price is typical for stock options that have vested over time.
- Similar transactions can be seen at companies like Biogen (BIIB) and Vertex Pharmaceuticals (VRTX), where executives regularly manage their stock holdings.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale by an executive.
- The sale does not indicate any change in the company's operations or outlook.
Key Dates
| Date | Description |
|---|---|
| 01/02/2019 | Start date for the vesting of the options in three annual tranches. |
| 11/20/2024 | Date of the option exercise and subsequent sale of shares. |
| 11/22/2024 | Date of the filing of the SEC Form 4. |
| 01/02/2025 | Expiration date of the options. |
Keywords
Catalyst Pharmaceuticals, stock options, insider trading, share sale, executive compensation, CPRX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.